Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1046 | 988 | 1046 | 1083 | 1202 | 2002 |
Fund Return | 4.62% | -1.23% | 4.62% | 2.71% | 3.75% | 7.19% |
Place in category | 270 | 211 | 270 | 138 | 112 | 29 |
% in Category | 75 | 54 | 75 | 39 | 38 | 12 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Liontrust Special Situations Fund A | 2.74B | 2.65 | -1.22 | 7.53 | ||
Liontrust Special Situations Fund I | 2.08B | 2.91 | -0.97 | 7.80 | ||
Liontrust Special Situations Fund R | 2.74B | 1.87 | -1.97 | 6.72 | ||
Liontrust European Growth Fund A In | 1.54B | 2.51 | 6.32 | 11.37 | ||
Liontrust European Growth Fund I In | 709.49M | 2.77 | 6.58 | 11.65 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Artemis UK Select Fund G Inc GBP | 798.49M | 25.65 | 10.73 | - | ||
Artemis UK Select Fund R Acc | 221.03M | 24.36 | 9.61 | 8.79 | ||
Artemis UK Select Fund I Acc | 1.9B | 25.30 | 10.43 | 9.63 | ||
Artemis UK Select Fund I Inc GBP | 210.65M | 25.31 | 10.43 | 9.44 | ||
Fidelity Special Situations | 3.2B | 3.70 | 8.00 | 7.16 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
AstraZeneca | GB0009895292 | 8.48 | 11,786.0 | +5.93% | |
Shell | GB00BP6MXD84 | 8.42 | 31.92 | -0.19% | |
Unilever | GB00B10RZP78 | 5.96 | 55.98 | +0.57% | |
BP | GB0007980591 | 5.13 | 429.00 | +1.19% | |
Relx | GB00B2B0DG97 | 4.09 | 4,043.00 | +0.30% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review